Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434944 | 1.00 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL29463415 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL524782 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL30205023 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| Hydrochloric Acid SCHEMBL23113141 | 0.95 | PARP1 (0.98) | PARP1PARP3 | |
| Hydrochloric Acid SCHEMBL29536089 | 0.95 | PARP1 (0.98) | PARP1PARP3 | |
| Hydrochloric Acid SCHEMBL22656793 | 0.95 | PARP1 (0.98) | PARP1PARP3 | |
| SCHEMBL22852663 | 0.93 | PARP1 (0.86) | PARP1PARP3 | |
| SCHEMBL30293115 | 0.92 | PARP1 (0.89) | PARP1PARP3 | |
| SCHEMBL30331782 | 0.91 | PARP1 (0.84) | PARP1PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043258-A1 | CRISPR-based DNA Repair-Inhibiting Intratumoral Cancer Therapy | RNA Therapeutics, Inc. (US) | 2025-02-06 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4618991-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Novartis AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20250043258-A1 | CRISPR-based DNA Repair-Inhibiting Intratumoral Cancer Therapy | RNA Therapeutics, Inc. (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| CN-116143700-B | Phthalazinone compound, and preparation method and application thereof | 沈阳药科大学 | 2024-06-28 | — | — | CN | disclosed |
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| WO-2024105610-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-7662818-B2 | e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662818-B2 | e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| WO-2008020180-A2 | METHODS OF INCREASING THE SENSITIVITY OF CANCER CELLS TO DNA DAMAGE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-21 | — | — | WO | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059663-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3029/4885PARP3 3491/4885 |
| US-20240197715-A1 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | WRN, RECQL, BLM | PARP1 30/4885PARP3 66/4885 |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885PARP3 4/4885 |
| US-20060149059-A1 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | PARP1 3176/4885PARP3 3644/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885PARP3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.